DB18894InvestigationalProtein Based Therapies
Visugromab is under investigation in clinical trial NCT06059547 (Neoadjuvant Immunotherapy in Combination With the Anti-gdf-15 Antibody Visugromab (CTL-002) for Treatment of Muscle Invasive Bladder Cancer).
- Mechanism
- Curator reviewed
Pharmacologically active on Growth/differentiation factor 15
- Code names
- CTL-002
Resolves to
Compound
Targets
What you can answer from here — as of July 09, 2026
Which drugs share a target with Visugromab, and which of those have an active Phase 3 trial?
Create a free account or log in to explore the full data card.
Create Account